General Announcement::GPL Announces Presentation of New Subtype Analysis of GBR 830

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
04-Mar-2019 11:58:53
Status
New
Announcement Sub Title
GPL Announces Presentation of New Subtype Analysis of GBR 830
Announcement Reference
SG190304OTHRLC4A
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
04/03/2019 09:26:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting

Attachments

PR_SGX_04032019_SIGNED.pdf
Total size =3176K